
Four new autoantigens trigger multiple sclerosis
Despite considerable progress in the treatment of multiplesclerosis (MS), the disease still often leads to permanent neurological disability....

ECBF oversubscribed closing at €300m
According to the industry experts, the biologisation of industrial production by means of sustainable bacterial-enzymatic or cell-culture-based...

Single-use market to reach $20.8bn by 2026
The "Global Forecast 2026" comprises Media Bags and containers, Bioreactors, Mixers, Assemblies, Applications (Cell Culture, Mixing,...

Sanofi and IGM Biosciences Inc. in $6.15bn deal
Under the agreement, IGM Biosciences Inc. (Mountain View) will discover IgM antibody agonists against three oncology targets and...

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

GeNeuro finds biologic against post-COVID syndrome
The results of a collaboration of GeNeuro with the FondaMental Foundation were presented at the Schizophrenia International Research Society (SIRS)...

Meletios Therapeutics licences antiviral patent
Meletios has signed an exclusive license agreement with Institut Pasteur to commercialise Defective Viral Genomes (DVG). DVGs are truncated or...